GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Supernus Pharmaceuticals
Supernus is a pharmaceutical company specializing in the treatment of central nervous system (CNS) disorders. Its stock price is driven by sales of its core products and progress in developing new drugs for epilepsy, ADHD, and depression.
Share prices of companies in the market segment - Neuro
Supernus is a pharmaceutical company specializing in the treatment of central nervous system disorders. We classify it in the pharmaceuticals (neurology) sector, and the chart below reflects general trends and investor sentiment in this sector.
Broad Market Index - GURU.Markets
Supernus Pharmaceuticals is a pharmaceutical company specializing in the development of drugs for the treatment of central nervous system diseases. Its focus on neuroscience makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Supernus compares to it.
Change in the price of a company, segment, and market as a whole per day
SUPN - Daily change in the company's share price Supernus Pharmaceuticals
Daily fluctuations in Supernus Pharmaceuticals, which focuses on CNS diseases, reflect news from the pharmaceutical sector. Change_co measures volatility associated with drug sales and research results. At System.GURU.Markets, this indicator is used in formulas for assessing stability and risk in specialty pharmaceuticals.
Daily change in the price of a set of shares in a market segment - Neuro
Supernus Pharmaceuticals, Inc. is a pharmaceutical company. This chart highlights the sector's high volatility. Comparing it to SUPN, which focuses on CNS diseases, helps assess its risk compared to more diversified pharmaceutical companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Supernus is a pharmaceutical company specializing in drugs for the treatment of central nervous system disorders. Neuroscience is a risky area of research. The chart below illustrates the high volatility typical of the biotech sector, reflecting the stakes associated with Supernus's developments.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Supernus Pharmaceuticals
Supernus is a biopharmaceutical company specializing in the treatment of diseases of the central nervous system. Its year-over-year performance reflects both the commercial success of its existing drugs and investor confidence in its R&D platform.
Annual dynamics of market capitalization of the market segment - Neuro
Supernus Pharmaceuticals, Inc. is a pharmaceutical company specializing in the treatment of diseases of the central nervous system. Its strategy includes both proprietary drug development and acquisitions. The chart below shows how its commercialized product portfolio and R&D results influence its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Supernus is a biopharmaceutical company whose stock performance is driven by sales success of its CNS drugs and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Supernus Pharmaceuticals
The performance of Supernus, a pharmaceutical company, depends on its product cycle. The monthly fluctuations on the chart reflect sales data for its drugs for treating central nervous system disorders, such as ADHD and epilepsy, as well as news about clinical trials of new candidates in its portfolio.
Monthly dynamics of market capitalization of the market segment - Neuro
Supernus Pharmaceuticals specializes in the treatment of central nervous system disorders. The company focuses on commercializing already approved drugs and expanding their use. The pharmaceutical sector dynamics chart will show overall investor interest in the industry, which can be used to assess Supernus's commercial success and growth strategy.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Supernus Pharmaceuticals is a pharmaceutical company specializing in diseases of the central nervous system. The healthcare sector is considered "defensive." Amid the market fluctuations shown in the chart, Supernus's performance is determined primarily by the successful sales of its drugs and news about clinical developments, rather than the state of the economy.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Supernus Pharmaceuticals
The weekly performance of Supernus Pharmaceuticals, a company specializing in central nervous system diseases, is driven by pharmaceutical news. Its stock price reacts to sales data for key drugs, clinical trial results, and regulatory decisions. The chart below shows how short-term events in this niche influence the company's valuation.
Weekly dynamics of market capitalization of the market segment - Neuro
How typical are Supernus Pharmaceuticals' dynamics for the pharmaceutical sector? This chart compares the CNS-focused company's weekly stock price movements to the industry average. This helps us understand whether its reaction to sales and research news is typical, or whether its niche specialization creates a unique trajectory.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Supernus Pharmaceuticals specializes in drugs for the treatment of central nervous system disorders. This chart compares its weekly performance to the market. It helps understand whether its pipeline of approved drugs offers greater stability than that of biotechs in clinical trials.
Market capitalization of the company, segment and market as a whole
SUPN - Market capitalization of the company Supernus Pharmaceuticals
Supernus Pharmaceuticals' market capitalization reflects how investors value its portfolio of drugs for treating central nervous system disorders. The company's value depends on sales of its existing drugs and the success of its new developments. The chart illustrates how the market perceives its ability to compete in the complex neuroscience niche.
SUPN - Share of the company's market capitalization Supernus Pharmaceuticals within the market segment - Neuro
Supernus Pharmaceuticals specializes in developing and marketing drugs for the treatment of central nervous system disorders, such as ADHD and epilepsy. Its share of its sector market capitalization reflects its expertise in this complex field. The chart shows how investors value the sales of its existing products and the potential for new developments.
Market capitalization of the market segment - Neuro
This chart shows the total value of pharmaceutical companies specializing in central nervous system diseases. Supernus Pharmaceuticals is one of the leaders in this field. The dynamics on the chart reflect both the success of its commercial products and the risks associated with clinical development.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart reflects the economic weight of pharmaceuticals focused on diseases of the central nervous system. Supernus Pharmaceuticals' market capitalization is determined by the market valuation of its epilepsy and ADHD medications. The line shows how narrow specialization in a complex medical field is building a stable share of global healthcare.
Book value capitalization of the company, segment and market as a whole
SUPN - Book value capitalization of the company Supernus Pharmaceuticals
Supernus Pharmaceuticals' book value represents its scientific and commercial capital. The chart below reflects the valuation of its patents for drugs treating central nervous system diseases and its commercial infrastructure. The dynamics show how the company invests in the development of new drugs and their marketing.
SUPN - Share of the company's book capitalization Supernus Pharmaceuticals within the market segment - Neuro
Supernus's physical infrastructure includes R&D centers and manufacturing facilities for developing drugs for the treatment of central nervous system diseases. The chart shows the company's share of this specialized pharmaceutical infrastructure, which enables it to develop and commercialize innovative drugs.
Market segment balance sheet capitalization - Neuro
Supernus Pharmaceuticals is a commercial pharmaceutical company. It not only develops but also markets its drugs, which requires investment in production and supply chains. The graph will show whether this mixed model (science and commercialization) is the norm for the entire pharmaceutical industry.
Book value of all companies included in the broad market index - GURU.Markets
Supernus Pharmaceuticals' assets include intellectual property for drugs treating central nervous system diseases and the infrastructure for their promotion. Its book value reflects the capital invested in the development and commercialization of drugs in the complex field of neurology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Supernus Pharmaceuticals
Supernus Pharmaceuticals specializes in treating diseases of the central nervous system. Its balance sheet reflects its R&D and manufacturing assets, while its market capitalization represents its portfolio of commercialized drugs and pipeline. The chart shows how the market perceives its ability to successfully market existing drugs and develop new ones.
Market to book capitalization ratio in a market segment - Neuro
Supernus Pharmaceuticals is a pharmaceutical company specializing in the treatment of central nervous system diseases. Its value is determined by its portfolio of approved drugs and developments. The chart shows how the market values its intellectual property and ability to commercialize its products.
Market to book capitalization ratio for the market as a whole
Supernus Pharmaceuticals is a pharmaceutical company specializing in the treatment of diseases of the central nervous system. The chart shows how the market values the company with a portfolio of commercialized drugs. Its value is determined by the sales volume of its existing drugs and the potential of new products in development, creating a premium to its tangible assets.
Debts of the company, segment and market as a whole
SUPN - Company debts Supernus Pharmaceuticals
Supernus Pharmaceuticals specializes in developing drugs for the treatment of central nervous system diseases. The company's debt load may reflect its strategy of acquiring already approved drugs or funding late-stage clinical trials of its own developments, which allows it to accelerate market entry.
Market segment debts - Neuro
Supernus Pharmaceuticals specializes in developing drugs for the treatment of central nervous system diseases. The company has successfully commercialized several products, which distinguishes it from many biotech companies. This chart shows common financial metrics for the pharmaceutical industry, allowing one to assess how Supernus uses sales revenue to fund new developments.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Supernus Pharmaceuticals
Supernus Pharmaceuticals is a pharmaceutical company specializing in the treatment of central nervous system disorders. Bringing a new drug to market requires significant R&D and marketing expenditures. This chart shows how the company finances its growth, balancing reinvestment of profits from existing products with the acquisition of debt.
Market segment debt to market segment book capitalization - Neuro
Supernus Pharmaceuticals specializes in treating central nervous system disorders such as epilepsy and ADHD. This chart compares the company's debt used for drug development and commercialization to the total market capitalization of the entire neuroscience pharmaceutical sector. It helps evaluate its financial strategy in this complex area of medicine.
Debt to book value of all companies in the market
Supernus Pharmaceuticals operates in the stable healthcare sector. This chart compares its debt to the overall book value of the economy. It helps assess the company's financial conservatism and how its niche strategy compares to overall macroeconomic trends.
P/E of the company, segment and market as a whole
P/E - Supernus Pharmaceuticals
This chart shows the valuation of Supernus Pharmaceuticals, a company specializing in the treatment of central nervous system diseases. The metric reflects how investors view its existing drug portfolio and their confidence in the success of its new developments. It is sensitive to news about clinical trials and regulatory decisions.
P/E of the market segment - Neuro
This chart shows the average valuation for the specialty pharmaceutical sector in which Supernus operates. This metric reflects how investors generally value companies operating in niches with high barriers to entry. It helps understand whether Supernus's valuation reflects a premium for its CNS drug portfolio.
P/E of the market as a whole
Supernus Pharmaceuticals is a pharmaceutical company specializing in the development and commercialization of drugs for the treatment of central nervous system disorders, such as epilepsy and ADHD. The company is focused on improving the quality of life for patients. This risk appetite chart helps understand how investors value specialty pharmaceutical companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Supernus Pharmaceuticals
Supernus Pharmaceuticals specializes in drugs for the treatment of central nervous system disorders, such as epilepsy and ADHD. This chart shows market expectations for future sales of its drugs and the success of new developments. It assesses the company's ability to compete and innovate in the complex field of neuroscience.
%20P%2FE%20Supernus%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Supernus-Pharmaceuticals&v=1772513861488 "Chart of the company's future (projected) P/E Supernus Pharmaceuticals")
Future (projected) P/E of the market segment - Neuro
Supernus Pharmaceuticals is a pharmaceutical company specializing in the development and commercialization of products for the treatment of central nervous system (CNS) disorders, including epilepsy and ADHD. This chart shows overall market sentiment regarding the biotech sector, helping to assess Supernus's potential relative to expectations across the neuroscience industry.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772513861496 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Supernus Pharmaceuticals specializes in the treatment of central nervous system disorders. The company's success depends on the commercialization of its drugs and progress in developing new ones. Demand for medications for conditions such as ADHD and epilepsy is stable, making Supernus's business resistant to market cycles.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513861506 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Supernus Pharmaceuticals
Supernus Pharmaceuticals is a pharmaceutical company specializing in the development and commercialization of drugs for the treatment of central nervous system (CNS) disorders. Its profits depend on sales of key ADHD and epilepsy drugs. This chart shows how patent protection, competition, and successful new product launches impact financial stability.
Profit of companies in the market segment - Neuro
Supernus Pharmaceuticals is a pharmaceutical company specializing in the development and commercialization of drugs for the treatment of central nervous system (CNS) diseases. This chart shows the profitability of the neuroscience segment. The company's success depends on its ability to bring new drugs to market and manage the life cycle of existing ones, which directly impacts the sector's performance.
Overall market profit
Supernus Pharmaceuticals specializes in developing medications for the treatment of central nervous system disorders, such as ADHD and epilepsy. Demand for these medications is driven by medical diagnoses, not economic conditions. This chart illustrates the general economic cycles within which Supernus addresses specific healthcare challenges, ensuring the stability of its business.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Supernus Pharmaceuticals
Supernus Pharmaceuticals is a pharmaceutical company specializing in the development of drugs for the treatment of central nervous system (CNS) disorders, such as epilepsy and ADHD. This chart reflects analysts' expectations for future earnings, which depend on sales of its existing products and the success of clinical development of new CNS drugs.
%20profit%20of%20the%20company%20Supernus%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Supernus-Pharmaceuticals&v=1772513861589 "Graph of future (projected) profit of the company Supernus Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Neuro
Supernus Pharmaceuticals specializes in the development and commercialization of drugs for the treatment of central nervous system (CNS) disorders. This chart shows revenue projections for the neuroscience segment. It reflects expectations for the launch of new drugs for conditions such as ADHD and epilepsy.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772513861592 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Supernus Pharmaceuticals specializes in treating central nervous system disorders such as epilepsy and ADHD. Demand for its medications is driven by medical needs, not the economy. However, the overall profit forecast reflected here impacts the investment climate in the healthcare sector and patients' ability to afford treatment through insurance plans.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513861610 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Supernus Pharmaceuticals
Supernus Pharmaceuticals specializes in drugs for the treatment of central nervous system disorders. The P/S for a company with an established product portfolio reflects how the market perceives the stability of its current sales and the potential for future revenue growth from its new developments.
P/S market segment - Neuro
Supernus Pharmaceuticals specializes in the development and commercialization of drugs for the treatment of central nervous system (CNS) disorders, such as epilepsy and ADHD. Their revenue depends on the success of their drugs. The chart shows how the market values their product portfolio and research in this complex but potentially lucrative area of medicine.
P/S of the market as a whole
Supernus Pharmaceuticals specializes in developing drugs for the treatment of central nervous system diseases. The company's revenue is generated through sales of its commercialized products. This chart shows the average revenue estimate, allowing one to assess how the market perceives the earnings of a pharmaceutical company operating in a complex but important therapeutic area.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Supernus Pharmaceuticals
Supernus Pharmaceuticals specializes in developing drugs for the treatment of central nervous system disorders, such as epilepsy and ADHD. This chart reflects investor expectations for future sales of its pipeline, taking into account the life cycles of existing products and the potential of new drugs in development.
%20P%2FS%20Supernus%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Supernus-Pharmaceuticals&v=1772513861641 "The graph of the company's future (projected) P/S Supernus Pharmaceuticals")
Future (projected) P/S of the market segment - Neuro
Supernus Pharmaceuticals, Inc. is a pharmaceutical company specializing in the development and commercialization of drugs for the treatment of central nervous system disorders, including epilepsy and ADHD. This chart compares its product sales expectations with those of other companies in the neuroscience sector, reflecting its market niche and development pipeline.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772513861645 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Supernus Pharmaceuticals specializes in developing drugs for the treatment of central nervous system disorders, such as epilepsy and ADHD. The company is focused on creating improved versions of existing medications. This chart reflects general sales expectations, and Supernus illustrates how incremental innovation in pharmaceuticals can create a stable and growing business.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513861648 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Supernus Pharmaceuticals
Supernus Pharmaceuticals is a pharmaceutical company specializing in the development and commercialization of drugs for the treatment of central nervous system (CNS) disorders, including epilepsy and ADHD. This chart shows the revenue from sales of its drug portfolio. Growth depends on the successful marketing of existing products and the approval of new drugs.
Sales of companies in the market segment - Neuro
Supernus Pharmaceuticals specializes in treating diseases of the central nervous system. This chart segments sales by its key drugs, such as Trokendi XR and Oxtellar XR. It allows investors to track the product lifecycle and assess the company's success in commercializing its developments.
Overall market sales
Supernus Pharmaceuticals is a pharmaceutical company specializing in the treatment of diseases of the central nervous system. Demand for its drugs is determined by medical needs, not the state of the economy. This schedule is not a significant factor for Supernus, whose success depends on the effectiveness of its drugs and its work with the medical community.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Supernus Pharmaceuticals
Supernus Pharmaceuticals specializes in drugs for the treatment of central nervous system disorders, such as epilepsy and ADHD. Its revenue forecast depends on sales of existing drugs and the success of new developments. This chart shows how analysts assess its ability to compete in the market and launch new products.
%20sales%20of%20the%20company%20Supernus%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Supernus-Pharmaceuticals&v=1772513861705 "Schedule of future (projected) sales of the company Supernus Pharmaceuticals")
Future (projected) sales of companies in the market segment - Neuro
Supernus Pharmaceuticals specializes in developing drugs for the treatment of central nervous system diseases. This chart shows projected revenue for the entire neuroscience pharmaceutical segment. It allows investors to assess whether analysts see growth potential in this complex area, which is critical to the commercial prospects of Supernus's drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772513861780 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Supernus Pharmaceuticals specializes in developing drugs to treat central nervous system disorders, such as ADHD and epilepsy. Demand for its products is driven by medical needs, not economics. However, the overall market environment, shown in the chart, influences investor sentiment, which influences the company's valuation and its ability to fund new developments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513861797 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Supernus Pharmaceuticals
Supernus Pharmaceuticals is a pharmaceutical company specializing in the treatment of central nervous system diseases. This chart shows how the company monetizes its developments. Its profitability is directly dependent on sales of key patented drugs and the success of developing and commercializing new drugs.
Market segment marginality - Neuro
Supernus Pharmaceuticals specializes in the development and marketing of drugs for the treatment of central nervous system disorders, such as epilepsy and ADHD. This metric reflects the commercial success of its products. High profitability reflects a strong market position protected by patents and high demand for its products.
Market marginality as a whole
Supernus Pharmaceuticals specializes in the treatment of central nervous system disorders. The company has a portfolio of existing drugs and is developing new ones. This overall profitability chart shows an average picture, while Supernus's success depends on the life cycle of its drugs, patent expirations, and clinical trial results.
Employees in the company, segment and market as a whole
Number of employees in the company Supernus Pharmaceuticals
Supernus Pharmaceuticals is a company specializing in the development of drugs for the treatment of central nervous system diseases. The growth of its commercial team, visible in the graph, is directly related to the launch of new drugs and the expansion of marketing efforts to increase sales among doctors and patients.
Share of the company's employees Supernus Pharmaceuticals within the market segment - Neuro
Supernus Pharmaceuticals is a pharmaceutical company specializing in the development and commercialization of drugs for the treatment of central nervous system (CNS) diseases. This chart highlights its expertise in neuroscience. It reflects the proportion of neuroscientists, clinicians, and sales professionals focused on CNS diseases that Supernus employs.
Number of employees in the market segment - Neuro
Supernus Pharmaceuticals is a pharmaceutical company specializing in the development of drugs for the treatment of central nervous system disorders. This chart illustrates its neuroscience workforce. The growing number of scientists in this field indicates progress in the treatment of conditions such as ADHD and epilepsy, which are key areas of Supernus's expertise.
Number of employees in the market as a whole
Supernus Pharmaceuticals is a pharmaceutical company specializing in the treatment of diseases of the central nervous system. The growth of its team, particularly in research and sales, reflects the successful launch of new drugs. This is an example of how medical innovations create commercial success and new jobs in a knowledge-intensive industry.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Supernus Pharmaceuticals (SUPN)
Supernus Pharmaceuticals is a pharmaceutical company specializing in the treatment of central nervous system diseases. Their value is determined by their pipeline of approved drugs and developments. This chart shows that intellectual property is a key value driver in the pharmaceutical industry, ensuring high capitalization per employee.
%20of%20the%20company%20Supernus%20Pharmaceuticals%20(SUPN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Supernus-Pharmaceuticals-SUPN&v=1772513862114 "Chart of market capitalization per employee (in thousands of dollars) of the company Supernus Pharmaceuticals (SUPN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Supernus is a pharmaceutical company specializing in the treatment of central nervous system (neurology) disorders. They have both approved drugs and ongoing R&D projects. This chart shows the industry average. It helps assess how the market values Supernus's hybrid model (R&D + sales) per employee in this complex therapeutic area.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772513862170 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Supernus Pharmaceuticals is a pharmaceutical company specializing in the treatment of diseases of the central nervous system. Developing brain drugs is one of the most complex areas of medicine. This chart reflects investors' appreciation for the scientific potential of the team working to develop new treatments for patients.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513862204 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Supernus Pharmaceuticals (SUPN)
Supernus Pharmaceuticals is a pharmaceutical company specializing in the treatment of central nervous system (CNS) diseases. The company has commercial products. This chart shows how successfully the sales team promotes these niche drugs to neurologists, and how revenue from them covers the costs of R&D staff searching for new drugs.
%20Chart%20Supernus%20Pharmaceuticals%20(SUPN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Supernus-Pharmaceuticals-SUPN&v=1772513862286 "Company Profit Per Employee (in thousands of dollars) Chart Supernus Pharmaceuticals (SUPN)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Supernus is a "specialty" pharma focused on treating CNS diseases (neurology, psychiatry). This chart shows the benchmark for "Specialty Pharma." In this sector, the benchmark is high. Revenue per employee is generated by "patents" on niche, "complex" drugs, which ensures high margins.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772513862442 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Supernus Pharmaceuticals specializes in the treatment of central nervous system disorders (epilepsy, ADHD). They focus on drugs with improved delivery. This is a niche pharmaceutical company. This graph shows the average market profit per employee. It helps understand how profitable the neuroscience R&D sector, where Supernus operates, is per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513862474 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Supernus Pharmaceuticals (SUPN)
Supernus Pharmaceuticals, a company specializing in the treatment of central nervous system diseases, demonstrates the commercial performance of its drug portfolio in this chart. The growth in revenue per employee reflects successful sales of key drugs and the company's ability to introduce new products to meet patient needs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Supernus-Pharmaceuticals-SUPN&v=1772513862476 "Sales chart per company employee Supernus Pharmaceuticals (SUPN)")
Sales per employee in the market segment - Neuro
Supernus Pharmaceuticals is a pharmaceutical company specializing in the treatment of central nervous system (CNS) diseases. This chart shows the average revenue per employee in this segment. It helps assess how productive Supernus's R&D and commercialization team is in the highly specialized neuroscience niche compared to its competitors.
Sales per employee for the market as a whole
Supernus Pharmaceuticals (SUPN) is a pharmaceutical company specializing in CNS diseases. The company has commercial products. This chart shows how successfully their sales team is promoting these drugs to physicians. An increase in this indicator means that sales revenue is outpacing the growth of administrative and R&D expenses.
Short shares by company, segment and market as a whole
Shares shorted by company Supernus Pharmaceuticals (SUPN)
Supernus Pharmaceuticals specializes in treating CNS (central nervous system) disorders such as epilepsy and ADHD. This chart highlights concerns about their pipeline. Market participants may bet on their new drugs not being approved or on their existing products facing stiff generic competition.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Supernus-Pharmaceuticals-SUPN&v=1772513862534 "Short Shares Chart for the Company Supernus Pharmaceuticals (SUPN)")
Shares shorted by market segment - Neuro
Supernus Pharmaceuticals specializes in treating central nervous system (CNS) disorders such as epilepsy and ADHD. This chart shows pessimism in the neuroscience pharmaceutical segment. The increase in short positions across the industry may indicate investors are concerned about generic competition for the company's key drugs or failures in new drug development.
Shares shorted by the overall market
Supernus Pharmaceuticals (SUPN) is a company specializing in the development and sale of drugs for the treatment of central nervous system disorders, such as epilepsy and ADHD. This chart measures overall market pessimism. The healthcare sector is considered "defensive" because patients continue to take medications for chronic conditions. This indicator shows whether investors believe demand for SUPN's drugs is stable during a downturn.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Supernus Pharmaceuticals (SUPN)
Supernus Pharmaceuticals focuses on drugs for the treatment of central nervous system diseases. Success depends on drug approval and sales. A chart above 70 may reflect strong sales or positive news from the FDA. A level below 30 is often associated with trial failures, delays, or competitive concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Supernus-Pharmaceuticals-SUPN&v=1772513862602 "RSI 14 indicator chart for the company's stock Supernus Pharmaceuticals (SUPN)")
RSI 14 Market Segment - Neuro
Supernus Pharmaceuticals is a company specializing in the development and marketing of drugs for the treatment of central nervous system (CNS) disorders, such as epilepsy, ADHD, and Parkinson's disease. This chart tracks the collective momentum in the CNS pharmaceutical sector. It helps understand whether the dynamics of SUPN are a response to its drugs or part of a general trend in the neurosegment.
RSI 14 for the overall market
Supernus (SUPN), a pharmaceutical company specializing in the central nervous system. This chart reflects sentiment in the sector. During periods of euphoria, investors are willing to fund R&D. During moments of panic, they seek companies with existing sales. SUPN, with both, may be more stable than pure biotechs.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SUPN (Supernus Pharmaceuticals)
Supernus Pharmaceuticals (SUPN) is a pharmaceutical company specializing in the treatment of central nervous system (CNS) disorders such as epilepsy, ADHD, and Parkinson's disease. The chart shows the average Wall Street forecast. It reflects analyst expectations for sales of key drugs (Qelbree, Trokendi) and progress in new drug development.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SUPN-Supernus-Pharmaceuticals&v=1772513862655 "A chart showing analyst consensus forecasts for the expected stock price. SUPN (Supernus Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price SUPN (Supernus Pharmaceuticals)
Supernus is a pharmaceutical company specializing in the development and sale of drugs for the treatment of central nervous system disorders (epilepsy, ADHD). This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the current share price and the consensus target price, demonstrating how confident experts are in their pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SUPN-Supernus-Pharmaceuticals&v=1772513862673 "A chart showing the difference between the consensus forecast and the actual stock price. SUPN (Supernus Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Neuro
Supernus Pharma is a niche pharmaceutical company specializing in developing drugs for the treatment of CNS (central nervous system) disorders such as epilepsy and ADHD. This chart shows analysts' overall expectations for the neuroscience sector, reflecting whether experts believe R&D success in this complex area is possible.
Analysts' consensus forecast for the overall market share price
Supernus Pharmaceuticals (SUPN) is a niche pharmaceutical manufacturer focused on neuroscience (CNS). They have approved products. This chart, reflecting expert expectations, doesn't impact their demand (diseases are non-cyclical). However, it does impact the risk appetite of investors evaluating their R&D pipeline.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Supernus Pharmaceuticals
Supernus is a pharmaceutical company specializing in central nervous system (CNS) disorders such as epilepsy and ADHD. This chart is an indicator of their commercial success. It likely aggregates the sales volumes of their key drugs (Trokendi, Oxtellar) and the market valuation of their R&D pipeline targeting other CNS disorders.
AKIMA Market Segment Index - Neuro
Supernus (SUPN) is a specialty pharmaceutical company focused on the CNS (central nervous system); the company develops and markets drugs for the treatment of epilepsy and ADHD. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does Supernus' niche (CNS) model differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
Supernus is a pharmaceutical company focused on the central nervous system (CNS). It develops and markets drugs for epilepsy, ADHD, and Parkinson's. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this protective scientific story compares to the overall economic trends affecting the sector.
